AKT1 and cholangiocarcinoma: These include some drugs, such as metformin, which sensitizes CCA cells to both sorafenib and 5-FU by reducing MRP1 expression through modulation of the AMPK/mTOR pathway [59] and simvastatin, that decreases CCA cell viability and ABCA1 and ABCG1 expression by acting through a pathway independent on the serine-threonine protein kinase AKT [60].